Consultation: antiparasitic and antiviral resistance

The JPIAMR has launched a round of consultation on antiparasitic and antiviral resistance. The information will be used for outlining research and innovation priorities in the Strategic Research and Innovation Agenda (SRIA) on Antimicrobial Resistance and informing the scope and direction of the candidate One Health AMR partnership. 

The (SRIA) presents an overview of recent developments and future needs for AMR research. More information and the link to the SRIA can be found here: JPIAMR Strategic Research and Innovation Agenda. The surveys have aim to map national and international funding in the area of antiparasitic and antiviral resistance.

National/country level funding survey

This survey has been designed to collect national input in extending the scope of the candidate One Health AMR partnership to include antiparasitic and antiviral resistance, and to show national willingness to commit funds to future activities dedicated to those topics. The survey should be submitted by national representatives only (one survey per country is expected).

Link to survey: https://survey.vr.se/Survey/773

A word template of the survey can be downloaded here and circulated for national consultation before submission: National/country level funding survey (Word file)

The outcomes of this survey will have an important impact on the future scientific directions taken by the JPIAMR and by the candidate OH AMR Partnership.

The survey will close on the 6th June 2022 at 12.00 CEST.

International funding survey

This survey has been designed to collect information on the international funding landscape for antiparasitic and antifungal research. The survey should be submitted by representatives from international funding organisations only (one survey per organisation is expected).

Link to survey: https://survey.vr.se/Survey/775

A word template of the survey can be downloaded here and circulated for organisational consultation before submission: International funding survey (Word file)

The outcomes of this survey will have an important impact on the future scientific directions taken by the JPIAMR and by the candidate OH AMR Partnership.

The survey will close on the 30th May 2022 at 12.00 CEST.

Illustration of Candida auris

Review from the JPIAMR SRIA fungal resistance group published in Nature Reviews Microbiology

JPIAMR is pleased to share the following review that was published in Nature Reviews Microbiology: Tackling the emerging threat of antifungal resistance to human health. The review was written by the expert group on antifungals that led the broadening on the JPIAMR Strategic Research and Innovation Agenda in 2021.

“Our review articulates the neglected aspect of antifungal resistance, and outlines where attention is needed to address this burgeoning problem. In particular, One-Health drivers require specific policy-led attention as it is here that agricultural practice conflicts with public health necessities – we hope that our article will focus attention on these increasingly urgent issues.” – Mat Fisher, Imperial College London, UK

The JPIAMR Strategic Research and Innovation Agenda was broadened in 2021 to include antifungal priorities for research and innovation.

“The article marks an important change in the JPIAMR Strategic Research and Innovation Agenda, which now incorporates antifungal resistance in its research goals. Fungal resistance proposals are eligible for funding in current and future calls, thereby enabling the international scientific community to address increasing challenges regarding the epidemiology, diagnosis and management of antifungal resistance.” – Paul E. Verweij, Radboud University Nijmegen Medical Center, the Netherlands

Scientific Research and Innovation Agenda picture

Strategic Research and Innovation Agenda – global survey

The JPIAMR has launched a round of public consultation on the Strategic Research and Innovation Agenda (SRIA) on Antimicrobial Resistance.  The (SRIA) presents an overview of recent developments and future needs for AMR research. More information and the link to the SRIA can be found here: JPIAMR Strategic Research and Innovation Agenda

The updated SRIA outlines five key priority topics within the AMR field: Therapeutics, Diagnostics, Surveillance Transmission and Evolution, and Prevention and Intervention.

The SRIA is a prime guiding tool for AMR research prioritisation in investments, research activities and planning for JPIAMR member states and other funding initiatives. It is also one of the most thorough guidelines on AMR research, helping researchers, policymakers, media, educators, health workers and the scientific community to work together on solutions to curb AMR on a global scale.

You can contribute to the consultation by completing the following survey: JPIAMR SRIA global survey

The survey will be closed on 15th April 2022 at 12.00 CET.

Call picture

Research call on drug resistance now open

The transnational project call Disrupting drug resistance using innovative design is now open. The call involves 27 funding organisations from 18 countries and the total estimated call budget is about 19 million Euro.

This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

The call will follow a two-step evaluation procedure and the deadline for pre-proposals is 8 March 2022.

Read more on the Disrupting drug resistance using innovative design call page.

Transmission dynamics 2016 call picture

Main achievements of the AMR Transmission Dynamics call

The outputs, outcomes and the impact generated by the projects supported under the 2016 JPIAMR joint co-funded call “AMR Transmission Dynamics have now been published in a report. The report highlights the effect of supporting excellent science through transnational research collaborations.

Numerous peer-reviewed scientific articles in highly recognised journals have been published by the supported projects on the research findings, and a patent has been filed on a new peptide molecule discovered in one of the projects.

Other impact highlights are:

  • New knowledge generation to address AMR at regional, national and global scale with a One Health approach.
  • Science-based policy and societal impact.
  • Innovative tools and analytical methods and technologies.
  • Interdisciplinary expertise in transnational collaboration.

Download the report (pdf 1 MB): 2016 call on AMR Transmission Dynamics: Research outputs, outcome and impact of the projects

AMR Transmission Dynamics call

The third JPIAMR joint co-funded call “AMR Transmission Dynamics” was launched in 2016. The call was conducted by 21 participating funding organisations from 18 countries and was co-funded by the European Commission (EC) within the JPI-EC-AMR ERA-Net co-fund grant . The call resulted in the awarding of 29.1 million euros (M EUR) including a 6.3 M EUR contribution from the EC to 19 research projects. The 19 project consortia included a total of 118 researchers from 16 countries aiming to bridge the knowledge gap on AMR transmission mechanisms.

The call was one of the first of its kind to address transmission of antibiotic resistance following a One Health approach not only focussing the European and North American countries but also including research activities in the low- and middle-income countries (LMIC).

Flag of Chile

Chile new member of JPIAMR

We are pleased to welcome Chile as a new member of JPIAMR. Chile’s participation in JPIAMR is part of the country’s determination to become an active contributor to the world’s efforts to tackle the global challenge of AMR.

Chile is represented in JPIAMR by MICROB-R on behalf of the Ministry of Health.

Tania Herrera, Coordinator Chile National AMR Plan:

-As an JPIAMR member, we expect to advance collaborative efforts on ambitious, innovative, large scale research projects, introducing meaningful progress in our knowledge base to tackle the global challenge of AMR.

Andrea Moreno Switt, Associate Professor, Pontificia Universidad Católica de Chile:

-In the context of Chile’s newly launched version of its AMR National Plan, JPIAMR membership represents our renewed efforts and conviction that Chilean agenda and capabilities on AMR research are having a substantial upgrade, and that we are in solid shape to undertake collaborative projects benefiting the international AMR research community.

Jan-Ingvar Jönsson, JPIAMR Chair:

On behalf of the JPIAMR Management Board, I am extending a warm welcome to Chile as the 29th member of JPIAMR. It is with great pleasure and excitement that we are including yet another country in Latin America. We are looking forward to create opportunities for researchers in Chile to participate in future calls. The membership will unlock new research collaborations that may contribute to a deeper understanding of AMR and potentially, solutions to one of the key challenges of our time.

Read more on Chile’s national AMR research program and activities.

JPIAMR celebrating 10 years

JPIAMR celebrating 10 years of achievements

It is with great pleasure that we acknowledge that JPIAMR officially celebrates ten years as an international collaborative platform. From its inception in December 2011 until today, JPIAMR has achieved and exceeded its mission to coordinate national funding of antimicrobial resistance (AMR) research, guided by a shared strategic research and innovation agenda. Today 28 countries fund AMR research with a One Health approach, as members of JPIAMR. More than 1 400 researchers in 71 countries have been engaged in research that has been funded by JPIAMR members. In total, 125 million Euros have been allocated to research and networking which has achieved outstanding results and impacts. This highlights the role of JPIAMR as a key initiative helping to understand and curb AMR on a global scale.

JPIAMR is leading the development of the One Health AMR Partnership within the Horizon Europe Framework Programme. We look forward to working together with members to seek and support solutions to curb AMR.

“It is impressive to see what JPIAMR members have made possible during these ten years. The results from funded research are astonishing and important, showing that the JPIAMR model works. JPIAMR is well suited to lead the development of the One Health AMR Partnership. We can only imagine what will be achieved in the ten years to come. I am joining all of the members and the AMR research community in wishing JPIAMR a Happy Birthday!” – Jan-Ingvar Jönsson, JPIAMR Chair

See highlights from JPIAMR’s ten year history in the folder “JPIAMR Ten years of achievements” (pdf 0,5 MB)

Call picture

Pre-announcement: Research call on drug resistance

We are pleased to pre-announce the transnational project call Disrupting drug resistance using innovative design under the umbrella of the JPIAMR. The call will involve 26 funding organisations from 17 countries and the total estimated call budget is about 17 million Euro.

This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

The call opens on 11 January 2022.

Read more on the Disrupting drug resistance using innovative design call page.

Diagnostics and Surveillance Networks call image

Pre-announcement: Diagnostics and surveillance network call

JPIAMR is launching the call Diagnostics and Surveillance Networks in April 2022 with the aim to assemble networks of leading experts and stakeholders with an intent to facilitate the development, optimisation and use of diagnostic and surveillance tools, technologies and systems.

Eleven (11) JPIAMR-ACTION members are participating in this network call to date. Each network coordinator will be able to apply for a maximum of 50,000 Euro for 12 or 24 months period for support of its activities.

Read more on the Diagnostics and Surveillance Networks call page.